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ABSTRACT 
Scrub typhus is a public health concern for a population of over a billion humans, with 
an estimated incidence of one million cases/year in endemic areas. Although 
doxycycline remains the standard therapy, fluoroquinolones have been used 
successfully in a few patients. However, there is also clinical evidence that 
fluoroquinolones are ineffective in the treatment of scrub typhus. To clarify this 
matter, we determined the in vitro susceptibility of Orientia tsutsugamushi strain Kato 
to ciprofloxacin and sequenced the quinolone resistance-determining region (QRDR) 
of the gyrA gene, the target of fluoroquinolones, of 18 fresh isolates from Lao PDR. 
Orientia tsutsugamushi strain Kato was resistant to ciprofloxacin and ofloxacin in vitro 
(minimum inhibitory concentration = 8 g/mL). All sequences obtained, including 
those from the two available genomes of O. tsutsugamushi (strains Boryong and 
Ikeda), had a Ser83Leu mutation in their QRDR domain that is known to be 
associated with fluoroquinolone resistance. These findings re-emphasise the 
usefulness of in silico analysis for the prediction of antibiotic resistance and suggest 
that fluoroquinolones should not be used in the treatment of scrub typhus. 
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1. Introduction 
Orientia tsutsugamushi, the agent of scrub typhus, is a small Gram-negative obligate 
intracellular bacterium of the alpha subgroup of Proteobacteria, transmitted to 
humans by the bite of trombiculid mites. The disease is a public health concern for a 
population of over a billion humans in a geographical triangle extending from 
northern Japan and far eastern Russia in the north, to northern Australia in the south 
and Pakistan and Afghanistan in the west [1–3]. The estimated incidence of the 
disease in endemic areas is one million cases/year. Although doxycycline and 
chloramphenicol remain the gold standard therapy for scrub typhus, ciprofloxacin has 
been shown to be effective in a mouse model [4] and in some anecdotal clinical 
cases [5–7]. However, recent reports of clinical failure and deaths as well as 
abortions in pregnant women with fluoroquinolone therapy suggest drug resistance in 
these cases [8–10]. Fluoroquinolone activity is due to inhibition of bacterial DNA 
gyrase (topoisomerase II) and topoisomerase IV. It has been demonstrated that 
resistance to quinolones in intracellular bacteria was mainly due to point mutations in 
the quinolone resistance-determining region (QRDR) of DNA gyrase (gyrA) [11,12]. 
Surprisingly, there are only a few reports regarding in vitro and/or in vivo antibiotic 
susceptibility in cell culture or animal models of O. tsutsugamushi, especially for 
fluoroquinolones. In the in vitro work of Kelly et al. [13], although they determined 
precisely the doxycycline minimum inhibitory concentration (MIC) against O. 
tsutsugamushi Karp strain, they tested only one high concentration of ciprofloxacin (4 
g/mL) that was found to be effective in vitro. Similarly, McLain et al. [4] found that 
ciprofloxacin was effective in preventing death in a mouse model of scrub typhus, but 
the appropriateness of such a mouse model to human disease is uncertain and the 
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dose (mg/kg body weight) of ciprofloxacin administered to mice was approximately 
six times the adult human dosage. With a lack of definitive data regarding the 
susceptibility of O. tsutsugamushi to fluoroquinolones, the objectives of this study 
were: (i) to determine the MIC of ciprofloxacin and ofloxacin against O. 
tsutsugamushi strain Kato using a modified real-time quantitative polymerase chain 
reaction (qPCR) assay previously used for Rickettsia spp. and Coxiella burnetii 
[14,15]; (ii) to amplify and sequence the gyrA gene of recent human O. 
tsutsugamushi isolates from Lao PDR (Laos); and (iii) to compare these sequences 
with those retrieved from available full sequenced genomes of strains Boryong [16] 
and Ikeda [17] in order to decipher the possible molecular mechanism of resistance 
to fluoroquinolones. 
 
2. Materials and methods 
2.1. Patients and rickettsial culture 
Patients were recruited to a study of the causes of fever [1]. Buffy coats, prepared 
from 5 mL of whole ethylene diamine tetra-acetic acid (EDTA)-anticoagulated venous 
blood from patients with suspected scrub typhus and serum immunoglobulin M (IgM) 
against O. tsutsugamushi detected by the scrub typhus immunochromatographic test 
(PanBio, Sinnamon Park, QLD, Australia), were cultured in Vero cells and L929 cells 
at 35 C in 10% fetal calf serum/RPMI in a 5% CO2 incubator [18]. DNA was 
extracted using High Pure PCR Template Preparation Kit (Roche Diagnostics, 
Meylan, France) and sent to URMITE (Marseille, France). 
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2.2. Preparation of Orientia tsutsugamushi inocula 
Orientia tsutsugamushi strain Kato (CSUR R163) was propagated in monolayers of 
L929 cells grown in minimum essential media (MEM) supplemented with 5% fetal 
bovine serum (FBS) and 2 mM L-glutamine (Invitrogen, Cergy-Pontoise, France). 
When almost 100% of the floating cells were infected, as determined by Giemsa 
(Merck, Darmstadt, Germany) staining, cells were harvested, disrupted by glass 
beads (diameter 3 mm) and centrifuged at 500  g for 5 min at 4 C. The supernatant 
containing O. tsutsugamushi was centrifuged again at 2000  g for 10 min at 4 C to 
collect the bacterial pellet. Orientia tsutsugamushi was cryopreserved in MEM 
containing 20% FBS and 5% dimethyl sulphoxide (DMSO) and stored at –80 C until 
use. The infectivity titre of inocula was determined as described previously [19] with 
slight modification. Briefly, the inoculum was five-fold serially diluted and inoculated 
onto L929 cells grown in a 24-well plate. After 2 h of inoculation, the inoculum was 
removed and replaced by new media containing 0.4 g/mL daunorubicin (BIOMOL, 
Lausen, Switzerland), which partially inhibits the growth of host cells [20]. After 2 
days of incubation, cells were collected and stained by indirect immunofluorescence 
assay using pooled human sera from Thai patients [2] with scrub typhus at a dilution 
of 1/400. Fluorescein isothiocyanate (FITC)-conjugated goat anti-human IgG 
(FluolineG; bioMérieux, Marcy l’Etoile, France) diluted at 1/200 was used as the 
secondary antibody. The infected cell counting units (ICU) of O. tsutsugamushi were 
calculated from the dilution in the well in which 5–25% of cells were infected, using 
the formula ICU = total number of cells  percentage of infected cells/100  dilution 
factor. 
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2.3. Antibiotic susceptibility testing 
Growth of intracellular O. tsutsugamushi in cell culture with different concentrations of 
antibiotics was determined using real-time PCR with a TaqMan® probe as previously 
described for Rickettsia [15]. Briefly, 3  105 ICU of O. tsutsugamushi was inoculated 
onto monolayers of 1.5  105 L929 cells grown in 24-well plates. After incubation for 2 
h, the inoculum was removed and infected cells were washed with phosphate-
buffered saline. Infected cells were grown in media without antibiotic or with two-fold 
serial dilutions of antibiotics and were incubated at 37 C in a humidified atmosphere 
with 5% CO2. Cell monolayers were harvested by trypsinisation and the cell 
suspension was centrifuged to collect cell pellets. Samples were collected every 24 h 
throughout the 5-day experiments. Experiments were repeated twice and each 
experiment was performed in duplicate. Cell pellets containing intracellular O. 
tsutsugamushi were processed for DNA extraction using QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. The DNA copy 
number of O. tsutsugamushi was quantified using a real-time PCR targeting the rpoB 
gene. The sequence of the primers and the TaqMan probe were as follows: rpoB F 
(3235–3257), 5’-AAG CAT AGG TTA CAG CCT GGW GA-3’; rpoB R (3346–3373), 
5’-ACC CCA ACG GAT TTA ATA CTA TAT CWA C-3’; and rpoB probe R (3307–
3338), 5’-FAM-CCA TCT TCA AGA AAT GGC ATA TCT TCC TCA GG- TAMRA-3’. 
The real-time PCR mixture contained 1 QuantiTect Probe PCR Master Mix 
(Qiagen), 0.5 M forward and reverse primers, 0.2 M probe, sterile distilled water 
and 5 L of DNA. Real-time PCR was performed in a Smart Cycler Instrument 
(Cepheid, Paris, France) with the following conditions: initial denaturation at 95 C for 
15 min, followed by 40 cycles of denaturation at 94 C for 5 s and combined 
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annealing and extension at 60 C for 60 min with the acquisition of fluorescence. The 
number of DNA copies was calculated using the standard curve technique. 
 
2.4. Determination of the quinolone resistance-determining region of gyrA and protein 
sequences alignment 
Eighteen strains of O. tsutsugamushi isolated from the blood of Lao patients with 
scrub typhus [1] were used for determination of the QRDR sequence of gyrA. DNA 
was extracted from the blood sample (buffy coat layer) using a QIAamp DNA Mini Kit 
(Qiagen) according to the manufacturer’s instructions. Primers used for partial gyrA 
amplification and sequencing were as follows: TsgyrAF, 5’-
TATGCTATGAGCGTAATAGT-3’; and TsgyrAR, 5’-TGCCATTCCTACTGCAATTC-3’. 
Finally, the partial gyrA sequences of the QRDR of O. tsutsugamushi were aligned 
using the CLUSTAL W program (http://www.ebi.ac.uk/clustalw/) to look at possible 
mutations known to be associated with fluoroquinolone resistance. The gyrA protein 
sequences of O. tsutsugamushi strain Boryong (OTBS_0252) and Ikeda (OTT_1379) 
and Escherichia coli K12 (b2231) retrieved at the KEGG website 
(http://www.genome.jp/) were used for comparison of positions within the gene. 
 
3. Results and discussion 
In the real-time qPCR assay, the MIC determined in duplicate against ciprofloxacin 
and ofloxacin for O. tsutsugamushi strain Kato was 8 g/mL (Fig. 1). Experiments 
were carried out twice to confirm the results. Compared with E. coli, the QRDR 
region of gyrA of the 18 Lao O. tsutsugamushi isolates as well as those retrieved 
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from the KEGG website (strains Boryong and Ikeda) displayed an intrinsic Ser83Leu 
mutation (Fig. 2). Moreover, 19 of the 20 sequences had a Thr88Ser mutation, 1 
isolate had a Thr88Ala mutation and all 20 protein sequences had an Ile89Leu 
mutation. Thus, looking at in vitro and in silico results, it was found that O. 
tsutsugamushi strain Kato was intrinsically resistant to ciprofloxacin and that all 
available sequences of the O. tsutsugamushi QRDR domain of gyrA had an intrinsic 
mutation at position 83 known to be associated with fluoroquinolone resistance, as 
has been established in other intracellular bacteria including Ehrlichia spp., 
Bartonella spp. and Tropheryma whipplei [11,12]. Therefore, these data provide 
evidence that O. tsutsugamushi is naturally resistant to fluoroquinolones, explaining 
clinical failures reported using such antibiotics in the treatment of scrub typhus. 
Indeed, there are several reports demonstrating that ciprofloxacin is not effective in 
the treatment of scrub typhus (Table 1). In an outbreak in Southern India, among 28 
patients serologically confirmed to have scrub typhus, 17 patients treated with 
doxycycline and 2 patients treated with chloramphenicol recovered in 1–3 days [9]. 
However, in five patients who received ciprofloxacin, fever subsided only after 5 
days. Three patients (10.7%) died, including one patient treated with doxycycline and 
two with fluoroquinolones, indicating a possibility of drug resistance [9]. Similarly, we 
have reported five pregnant Indian patients with scrub typhus, four of whom were 
treated initially with ciprofloxacin [8]. Three women had stillbirths, one an abortion 
and one a low birth weight baby [8]. Scrub typhus has also been transmitted by 
needle stick from a patient who received pefloxacin [21]. Finally, Tsai et al. [10] have 
shown recently in a retrospective case series of 132 patients with scrub typhus that 
although treatment with levofloxacin was effective in 71 patients, the patients had a 
significantly longer time to defervescence compared with 61 patients treated with 
Page 10 of 18
Ac
ce
pte
d M
an
us
cri
pt
10 
 
tetracyclines. Moreover, for patients with severe scrub typhus, higher mortality was 
observed in the levofloxacin-treated group [10]. There are three reports of apparent 
successful scrub typhus therapy with fluoroquinolones [5,6,22], although the 
evidence for scrub typhus as the aetiology of the disease is uncertain for one patient 
[5]. Our in vitro and in silico findings re-emphasise the usefulness of such analysis for 
prediction of antibiotic resistance in intracellular bacteria. These results suggest that 
fluoroquinolones should not be used for the treatment of scrub typhus. 
Fluoroquinolones remain efficacious for the therapy of uncomplicated typhoid fever in 
much of Asia. Therefore, with the difficulty in clinically distinguishing typhus from 
typhoid, innate resistance in O. tsutsugamushi to fluoroquinolones has important 
practical implications for the empirical treatment of undifferentiated fever in Southeast 
Asia, suggesting that fluoroquinolones are unlikely to have sufficiently broad 
pathogen coverage. 
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Fig. 1. Growth curves of Orientia tsutsugamushi in L929 cells with different 
concentrations of (A) ciprofloxacin and (B) ofloxacin. The number of bacteria was 
expressed as log DNA copies. Experiments were repeated twice and each 
experiment was performed in duplicate. Data in the figure represent mean ± standard 
deviation. 
 
Fig. 2. (A) DNA sequence alignment of the quinolone resistance-determining region 
(QRDR) domain of the gyrA genes of Orientia tsutsugamushi strains from Laos and 
from genomes of strains Boryong and Ikeda showing the Ser83Leu mutation 
(Escherichia coli numbering); and (B) three-dimensional representation of DNA 
gyrase showing position 83 in the QRDR. 
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Table 1 
Epidemiological and clinical data on fluoroquinolone therapy for scrub typhus 
Patient [age 
(years)] 
Country Antibiotic Outcome Reference 
Female (32) Thailand Cefotaxime + 
ofloxacin 
Cured [5] 
Male (34) Sri 
Lanka 
Doxycycline + 
ciprofloxacin 
Cured [7] 
Male (20) Korea Pefloxacin + 
cefazolin 
Clinical deterioration [20] 
Female (17) a India Ciprofloxacin No improvement; 
stillbirth 
[8] 
Female (20) a India Ciprofloxacin No improvement; 
stillbirth 
[8] 
Female (24) a India Ciprofloxacin + 
ampicillin 
No  
improvement; low birth 
weight baby 
[8] 
Female (21) a India Ciprofloxacin No improvement; 
abortion 
[8] 
Male and 
female patients 
(n = 5) 
India Ciprofloxacin Longer time to 
defervescence 
[9] 
Male and 
female patients 
(n = 71) 
Taiwan Levofloxacin Longer time to 
defervescence; 4 
deaths 
[10] 
a Pregnant women. 
Edited Table 1
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Ser83Leu
A
B
2072            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2144            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2002            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2309            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
Kato            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2391            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2418            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2304            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2382            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2325            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2223            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2261            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
Boryong         HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2259            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2395            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2281            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2289            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
Ikeda           HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2415            HYNKQYRKSARVVGDVIGKYHPHGELAVYDALVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2193            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
2328            HYNKQYRKSARVVGDVIGKYHPHGELAVYDSLVRMAQDFSLRLPLVDGQGNFGSMDGDAA 
eco             DWNKAYKKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDSA 
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Edited Figure 2
